

Supplemental Appendix to *Risk of depression, suicidal ideation, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: a multi-national network cohort study*

Jennifer C.E. Lane, James Weaver, Kristin Kostka, Talita Duarte-Salles, Maria Tereza F. Abrahao, Heba Alghoul, Osaid Alser, Thamir M Alshammari, Carlos Areia, Patricia Biedermann, Juan M. Banda, Edward Burn, Paula Casajust, Kristina Fišter, Jill Hardin, Laura Hester, George Hripcak, Benjamin Skov Kaas-Hansen, Sajan Khosla, Spyros Kolovos, Kristine E. Lynch, Rupa Makadia, Andrea V. Margulis, Michael E. Matheny, Paras P. Mehta, Daniel R. Morales, Henry Morgan-Stewart, Mees Mosseveld, Danielle Newby, Fredrik Nyberg, Anna Ostropolets, Rae Woong Park, Albert Prats-Uribe, Gowtham A. Rao, Christian Reich, Peter Rijnbeek, Anthony G. Sena, Azza Shoabi, Matthew Spotnitz, Vignesh Subbian, Marc A. Suchard, David Vizcaya, Haini Wen, Marcel de Wilde, Junqing Xie, Seng Chan You, Lin Zhang, Simon Lovestone, Patrick Ryan, and Daniel Prieto-Alhambra

Contents

1.	Literature review sources	2
1.1.	PubMed search strategy	2
1.2.	EMBASE search strategy (1974 to present)	2
2.	Data Sources	3
3.	Cohort definitions	4
3.1.	Exposures	4
3.1.1.	New users of Hydroxychloroquine with prior rheumatoid arthritis	4
3.1.2.	New users of sulfasazine with prior rheumatoid arthritis	5
3.2.	Outcomes	6
3.2.1.	Depression	6
3.2.2.	Suicide and suicidal ideation	7
3.2.3.	Hospitalization for psychosis	7
4.	Negative control outcomes	8
5.	Covariate construction	9
6.	Study population counts	10
7.	Patient baseline characteristics before and after propensity score stratification.....	11
7.1.	AmbEMR.....	11
7.2.	CCAE	13
7.3.	Clininformatics	14
7.4.	CPRD	16
7.5.	DAGermany	17
7.6.	IMRD	19
7.7.	MDCD	21
7.8.	MDCR.....	23
7.9.	OpenClaims	24
7.10.	OptumEHR	26
8.	Study diagnostics	28
8.1.	Diagnostics (AmbEMR, CCAE, Clininformatics, CPRD, DAGermany)	29
8.2.	Diagnostics (IMRD, MDCD, MDCR, OpenClaims, OptumEHR)	30
9.	Incidence rates	31
9.1.	30-day follow-up	31
9.2.	On-treatment follow-up.....	31

1. Literature review sources

1.1. PubMed search strategy

((((((("schizophrenia spectrum and other psychotic disorders"[mesh terms])) or (depressive disorder[mesh terms])) or (suicide, completed[mesh terms])) or (suicidal ideation[mesh terms])) or (suicide, attempted[mesh terms])) or (psychotic disorders[mesh terms])) or (psychos*[title/abstract])) or (psychot*[title/abstract])) or (depress*[title/abstract])) or (suicid*[title/abstract])) and (((((((("hydroxychloroquine"[mesh terms]) or (hydroxychloroquine[title/abstract])) or (chloro quinol[title/abstract])) or (ercoquin[title/abstract])) or (hydroxychloroquine[title/abstract])) or (hydrochloroquine[title/abstract])) or (oxychloroquine[title/abstract])) or (plaquenil[title/abstract])) or (quensyl[title/abstract])))

1.2. EMBASE search strategy (1974 to present)

1	schizophren* ti/ab	158752
2	depress* ti/ab	604149
3	psychos* ti/ab	213154
4	psychot* ti/ab	134304
5	suicid* ti/ab	95992
6	1 OR 2 OR 3 OR 4 OR 5	1016578
7	(Hydroxychloroquine).ti,ab	7869
8	(chloroquinol).ti,ab	2
9	(ercoquin).ti,ab	0
10	(hydrochloroquine).ti,ab	57
11	(hydrocloroquine).ti,ab	0
12	(oxychloroquine).ti,ab	6
13	(plaquenil).ti,ab	308
14	(quensyl).ti,ab	4
15	("sn 8137").ti,ab	1
16	HYDROXYCHLOROQUINE/	23778
17	7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16	24407
18	17 AND 6	451

2. Data Sources

Database name	Abbreviation	Population	Patients (millions)	Data History	Data capture process and short database description
IQVIA US Ambulatory EMR	AmbEMR	USA (General population)	49M	2006 –	General practice EHR, Outpatient specialist EHR - Dataset consists of longitudinal, de-identified ambulatory electronic health records data
IBM MarketScan Commercial Claims	CCAE	USA (Patients with commercial insurance aged <65 years)	142M	2000 –	Data from individuals enrolled in US employer-sponsored insurance health plans. The data includes adjudicated health insurance claims (e.g. inpatient, outpatient, and outpatient pharmacy) as well as enrollment data from large employers and health plans who provide private healthcare coverage to employees, their spouses, and dependents. Additionally, it captures laboratory tests for a subset of the covered lives.
Optum de-identified Clininformatics® Data Mart Database	Clininformatics	USA (Patients with commercial insurance or commercial Medicare insurance)	85M	2000 –	Adjudicated administrative health claims database for members of private health insurance, who are fully insured in commercial plans or in administrative services only (ASOs) and commercial Medicare. Represents inpatient and outpatient medical services and prescriptions as dispensed, as well as results for outpatient lab tests processed by national lab vendors.
Clinical Practice Research Datalink	CPRD	UK (General population)	13M	1995 –	De-identified patient data from a network of general practitioners' practices across the UK. Primary care data are linked to a range of other health related data to provide a longitudinal, representative UK population health dataset.
IQVIA Disease Analyzer Germany	DAGermany	Germany (General population)	37M	1992 –	Anonymized patient records collected from Patient Management software used by general practitioners and selected specialists to document patients' medical records within their office-based practice during a visit.
IQVIA UK Integrated Medical Record Data	IMRD	UK (General population)	15M	1989 –	Pseudonymized Electronic Medical Records collected from patient management software used within UK Primary Care
IBM MarketScan Multi-State Medicaid Database	MDCD	USA	26M	2006 –	Adjudicated US health insurance claims for Medicaid enrollees from multiple states and includes hospital discharge diagnoses, outpatient diagnoses and procedures, and outpatient pharmacy claims as well as ethnicity and Medicare eligibility.
IBM MarketScan Medicare Supplemental Database	MDCR	USA (Patients with commercial insurance aged 65+ years)	10M	2000 –	Represents health services of retirees (aged 65 or older) in the United States with primary or Medicare supplemental coverage through privately insured fee-for-service, point-of-service, or capitated health plans. These data include adjudicated health insurance claims (e.g. inpatient, outpatient, and outpatient pharmacy). Additionally, it captures laboratory tests for a subset of the covered lives.
IQVIA US LRxDx Open Claims	OpenClaims	USA (General population)	654M	2010 –	Pre-adjudicated claims at the anonymized patient level collected from office-based physicians and specialists via office management software and clearinghouse switch sources for the purpose of reimbursement.
Optum® de-identified Electronic Health Record Dataset	OptumEHR	USA (General population)	93M	2006 –	Optum's de-identified electronic health record data medical records database. The medical record data includes clinical information, inclusive of prescriptions as prescribed and administered, lab results, vital signs, body measurements, diagnoses, procedures, and information derived from clinical notes using Natural Language Processing (NLP).

3. Cohort definitions

To view the concept sets and source code lists used in each cohort definition, navigate to the URL following the name of each cohort. Then, navigate to the Concept Sets tab. The concept sets used in defining the outcome are listed on this page. After selecting a concept set to view, a user can explore the standard concepts used in the definition or the source codes from which the standard concepts are mapped. The full specification of each cohort, including computer readable JSON and SQL representations, are publicly available at the URLs for each definition.

3.1. Exposures

The index event was defined as the first recorded dispensing or prescription of HCQ or SSZ in a patient's history.

Exposure commenced on the first day of dispensing or prescription recorded with at least 365 days of prior observation period to increase confidence that the exposure was incident. Exposure interval gaps of ≤90 days (HCQ and SSZ) between drug dispensing or prescription records were allowed and inferred as persistent exposure. Drug discontinuation was considered if a patient switched from exposure to the other. Patients who switched contributed follow-up time to the exposure cohort that they entered first and were censored at the time of switching in the 'on treatment' analysis.

3.1.1. New users of Hydroxychloroquine with prior rheumatoid arthritis

<https://atlas.ohdsi.org/#/cohortdefinition/173>

Initial Event Cohort

People having any of the following:

- a drug exposure of [OHDSI Cov19] Hydroxychloroquine¹
 - for the first time in the person's history
 - with age >= 18

with continuous observation of at least 365 days prior and 0 days after event index date, and limit initial events to: **earliest event per person**.

Inclusion Rules

Inclusion Criteria #1: has rheumatoid arthritis recorded any time on or prior to treatment

Having any of the following criteria:

- at least 1 occurrence of a condition occurrence of [OHDSI Cov19] Rheumatoid arthritis²
where event starts between all days Before and 0 days After index start date
- or at least 1 occurrence of an observation of [OHDSI Cov19] Rheumatoid arthritis²
where event starts between all days Before and 0 days After index start date

Limit qualifying cohort to: **earliest event per person**.

End Date Strategy

Custom Drug Era Exit Criteria

This strategy creates a drug era from the codes found in the specified concept set. If the index event is found within an era, the cohort end date will use the era's end date. Otherwise, it will use the observation period end date that contains the index event.

Use the era end date of [OHDSI Cov19] Hydroxychloroquine¹

- allowing 90 days between exposures
- adding 0 days after exposure end

Cohort Collapse Strategy:

Collapse cohort by era with a gap size of 0 days.

3.1.2. New users of sulfasazine with prior rheumatoid arthritis

<https://atlas.ohdsi.org/#/cohortdefinition/45>

Initial Event Cohort

People having any of the following:

- a drug exposure of [OHDSI Cov19] sulfasalazine²
 - for the first time in the person's history

with continuous observation of at least 365 days prior and 0 days after event index date, and limit initial events to: **earliest event per person.**

Inclusion Rules

Inclusion Criteria #1: has rheumatoid arthritis recorded any time on or prior to treatment

Having all of the following criteria:

- at least 1 occurrence of a condition occurrence of [OHDSI Cov19] Rheumatoid arthritis¹
where event starts between all days Before and 0 days After index start date

Limit qualifying cohort to: **earliest event per person.**

End Date Strategy

Custom Drug Era Exit Criteria

This strategy creates a drug era from the codes found in the specified concept set. If the index event is found within an era, the cohort end date will use the era's end date. Otherwise, it will use the observation period end date that contains the index event.

Use the era end date of [OHDSI Cov19] sulfasalazine²

- allowing 90 days between exposures
- adding 0 days after exposure end

Cohort Collapse Strategy:

Collapse cohort by era with a gap size of 0 days.

3.2. Outcomes

3.2.1. Depression

<https://atlas.ohdsi.org/#/cohortdefinition/237>

Initial Event Cohort

People having any of the following:

- a condition occurrence of Depressive disorder³
 - for the first time in the person's history

with continuous observation of at least 365 days prior and 0 days after event index date, and limit initial events to: **earliest event per person.**

Inclusion Rules

Inclusion Criteria #1: No treatment more than 30 days prior

Having all of the following criteria:

- exactly 0 occurrences of a drug exposure of Antipsychotics¹
where event starts between all days Before and 30 days Before index start date
- and exactly 0 occurrences of a drug exposure of SSRI⁹
where event starts between all days Before and 30 days Before index start date
- and exactly 0 occurrences of a drug exposure of SNRI⁸
where event starts between all days Before and 30 days Before index start date
- and exactly 0 occurrences of a drug exposure of Tricyclic Anti-depressants¹⁰
where event starts between all days Before and 30 days Before index start date
- and exactly 0 occurrences of a drug exposure of Monoamine oxidase inhibitors (MAOI), non-selective⁵
where event starts between all days Before and 30 days Before index start date
- and exactly 0 occurrences of a drug exposure of Other antidepressants⁶
where event starts between all days Before and 30 days Before index start date

Inclusion Criteria #2: No prior psychoses/mania

Having all of the following criteria:

- exactly 0 occurrences of a condition occurrence of Dementia²
where event starts between all days Before and 0 days After index start date
- and exactly 0 occurrences of a condition occurrence of Mania⁴
where event starts between all days Before and 0 days After index start date
- and exactly 0 occurrences of a condition occurrence of Psychosis⁷
where event starts between all days Before and 0 days After index start date

Limit qualifying cohort to: **earliest event per person.**

End Date Strategy

No end date strategy selected. By default, the cohort end date will be the end of the observation period that contains the index event.

Cohort Collapse Strategy:

Collapse cohort by era with a gap size of 0 days.

3.2.2. Suicide and suicidal ideation

<https://atlas.ohdsi.org/#/cohortdefinition/235>

Initial Event Cohort

People having any of the following:

- a condition occurrence of Suicide and suicidal ideation1
- an observation of Suicide and suicidal ideation1

with continuous observation of at least 0 days prior and 0 days after event index date, and limit initial events to: **earliest event per person**.

Limit qualifying cohort to: **earliest event per person**.

End Date Strategy

No end date strategy selected. By default, the cohort end date will be the end of the observation period that contains the index event.

Cohort Collapse Strategy:

Collapse cohort by era with a gap size of 0 days.

3.2.3. Hospitalization for psychosis

<https://atlas.ohdsi.org/#/cohortdefinition/236>

Initial Event Cohort

People having any of the following:

- a visit occurrence of Inpatient visit1

with continuous observation of at least 0 days prior and 0 days after event index date, and limit initial events to: **all events per person**.

For people matching the Primary Events, include:

Having all of the following criteria:

- at least 1 occurrences of a condition occurrence of Psychosis²
 - condition type is any of Inpatient detail - primary, Inpatient header - primary, Primary Condition, Inpatient detail - 1st position, Inpatient header - 1st position, Outpatient detail - 1st position, Outpatient header - 1st position, Carrier claim header - 1st position, Carrier claim detail - 1st position

where event starts between all days Before and 0 days After index start date and event starts between 0 days Before and all days After index end date

Limit cohort of initial events to: **all events per person**.

Limit qualifying cohort to: **all events per person**.

End Date Strategy

Date Offset Exit Criteria

This cohort definition end date will be the index event's end date plus 0 days

Cohort Collapse Strategy:

Collapse cohort by era with a gap size of 0 days.

4. Negative control outcomes

Negative control outcomes are conditions believed to have no causal relationship with hydroxychloroquine, sulfasalazine, azithromycin, or amoxicillin exposure and therefore assumed *a priori* to return a hazard ratio (HR) of 1.0 when their risk is compared between exposure cohorts in a pairwise comparison. A HR of a negative control outcome that differs from 1.0 represents an estimate of the residual error of the analysis that was unaccounted for by the analytic specification such as propensity score adjustment. The distribution of residual error estimates from the negative control outcomes reflects a range of biases inherent to the analysis. The estimates on the negative control outcomes represents the empirical null distribution and we used it to compute hazard ratios and confidence intervals calibrated to reflect the observed residual error of the analysis. The negative controls were selected through a semi-automated process ² and are listed below with the corresponding SNOMED concept ID.

Concept ID	Concept Name	Concept ID	Concept Name
378256	Abnormal reflex	374375	Impacted cerumen
4092879	Absent kidney	4344500	Impingement syndrome of shoulder region
433753	Alcohol abuse	440382	Learning difficulties
321689	Apnea	435516	Lipoprotein deficiency disorder
78200	Benign mammary dysplasia	438808	Mammary duct ectasia
4195873	Breath smells unpleasant	441553	Myoclonus
443792	Calculus of bile duct	4119307	Neurogenic claudication
197318	Cholesterolosis of gallbladder	4209423	Nicotine dependence
439125	Complete trisomy 21 syndrome	313601	Oxygen supply absent
433270	Cord entanglement without compression	4091513	Passing flatus
4311591	Cramp in limb	4022076	Patient dependence on care provider
441267	Cystic fibrosis	439971	Poisoning by anticoagulant
436233	Delayed milestone	46286594	Problem related to lifestyle
40486120	Delay in physiological development	199876	Prolapse of female genital organs
374801	Foreign body in ear	4049367	Psychologic conversion disorder
259995	Foreign body in orifice	73754	Restless legs
196456	Gallstone	138821	Seborrhea
4166231	Genetic predisposition	4198492	Shoulder joint unstable
434164	Glycosuria	25518	Sickle cell trait
4163735	Hemochromatosis	4176908	Snapping thumb syndrome
439871	Hemospermia	4248728	Snoring
4058388	Hypertrophic scar	138278	Sprains and strains of joints and adjacent muscles
435522	Hypervitaminosis D	4008710	Stenosis due to any device, implant AND/OR graft
443236	Hypnotic or anxiolytic dependence	440233	Strain of supraspinatus muscle AND/OR tendon
4098604	Hypomagnesemia	4194160	Thyroid function tests abnormal
435371	Hypothermia	4216708	Urgent desire for stool
443447	Iatrogenic hypotension		

5. Covariate construction

The following consistently extracted set of baseline patient characteristics will be constructed for input in the PS model. From this large set of typically tens of thousands of covariates, key predictors of exposure classification will be selected for inclusion in the PS model. Note that not all data sources necessarily include data for all covariates. Covariates to be included:

- Demographics (age in 5-year bands, sex, race, ethnicity, index year, index month)
- All conditions occurrence records aggregated to SNOMED clinical finding level during the following lookback windows:
 - in 365 days prior to and including index date
 - in 30 days prior to and including index date
- All drug exposure records aggregated to RxNorm ingredient level and ATC classes during the following lookback windows:
 - in 365 days prior to and including index date
 - in 30 days prior to and including index date
 - persistent exposure that overlaps index date
- All procedure occurrence records during the following lookback windows:
 - in 365 days prior to and including index date
 - in 30 days prior to and including index date
- Measurements (including laboratories) within, above, and below normal range during the following lookback window:
 - in 365 days prior to and including index date
- Device exposure records during the following lookback windows:
 - in 365 days prior to and including index date
 - in 30 days prior to and including index date
- Comorbidity or risk scores including:
 - Charlson
 - DCSI
 - CHADS2
 - CHADS2VASc

6. Study population counts

The exposure cohort counts are calculated after the following study design criteria have been applied:

- Duplicate patients in the HCQ and SSZ with prior RA cohorts are removed from the cohort they qualified for second (i.e. retained in the cohort they qualified for first)
- Restricted to the calendar time when both exposures in the pairwise comparison (i.e. HCQ vs SSZ) are observed in the database.

After applying these design criteria to the original cohorts, the resulting patients are eligible to contribute data to study diagnostics and potentially to final population-level effect estimates.

Exposure	Database	Patients	Percent
Hydroxychloroquine with prior RA (n = 923,152)	AmbEMR	57,662	6.25
	CCAE	66,656	7.22
	Clininformatics	51,894	5.62
	CPRD	9,169	0.99
	DAGermany	3,966	0.43
	IMRD	8,855	0.96
	MDCD	7,994	0.87
	MDCR	15,765	1.71
	OpenClaims	621,124	67.28
	OptumEHR	80,067	8.67
Sulfasalazine with prior RA (n = 291,366)	AmbEMR	15,358	5.27
	CCAE	22,507	7.72
	Clininformatics	16,869	5.79
	CPRD	11,361	3.9
	DAGermany	5,136	1.76
	IMRD	8,463	2.9
	MDCD	2,301	0.79
	MDCR	5,281	1.81
	OpenClaims	183,566	63
	OptumEHR	20,524	7.04

7. Patient baseline characteristics before and after propensity score stratification

7.1. AmbEMR

Characteristic	Before PS stratification			After PS stratification		
	HCO	SSZ		HCO	SSZ	
%	%	Std. diff	%	%	Std. diff	
Age group						
15-19	0.1	0.1	0.00	0.1	0.1	0.00
20-24	0.7	0.6	0.01	0.7	0.6	0.01
25-29	1.3	1.4	-0.01	1.3	1.4	-0.01
30-34	2.4	2.2	0.02	2.3	2.2	0.01
35-39	3.5	3.7	-0.01	3.5	3.4	0.00
40-44	5.4	5.0	0.02	5.3	5.1	0.01
45-49	7.4	7.0	0.02	7.4	7.4	0.00
50-54	10.4	11.0	-0.02	10.5	10.4	0.00
55-59	13.1	13.4	-0.01	13.2	12.9	0.01
60-64	13.8	14.4	-0.02	13.9	14.1	-0.01
65-69	13.7	14.2	-0.01	13.8	13.7	0.00
70-74	13.1	13.3	-0.01	13.1	13.9	-0.02
75-79	11.2	9.8	0.05	10.9	10.9	0.00
80-84	3.9	3.9	0.00	3.9	3.7	0.01
Gender: female	79.7	74.1	0.13	78.3	78.4	0.00
Race						
race = Asian	1.4	1.5	-0.02	1.4	1.4	0.00
race = White	70.9	71.7	-0.02	71.1	71.3	0.00
race = African American	8.0	7.8	0.01	8.0	7.7	0.01
Ethnicity						
ethnicity = Hispanic or Latino	1.3	1.8	-0.04	1.4	1.5	-0.01
ethnicity = Not Hispanic or Latino	80.3	81.0	-0.02	80.5	80.4	0.00
Medical history: General						
Acute respiratory disease	13.5	14.2	-0.02	13.7	13.8	0.00
Attention deficit hyperactivity disorder	0.6	0.4	0.02	0.6	0.5	0.01
Chronic liver disease	1.5	1.5	0.00	1.5	1.4	0.01
Chronic obstructive lung disease	7.0	7.2	-0.01	7.1	6.9	0.01
Crohn's disease	0.4	1.1	-0.08	0.5	0.6	-0.02
Dementia	0.6	0.5	0.02	0.6	0.6	0.00
Depressive disorder	15.0	14.4	0.02	14.8	14.8	0.00
Diabetes mellitus	13.2	13.2	0.00	13.2	13.7	-0.01
Gastroesophageal reflux disease	15.9	14.6	0.04	15.6	15.7	0.00
Gastrointestinal hemorrhage	1.2	1.2	0.00	1.2	1.2	0.00
Human immunodeficiency virus infection	0.1	0.1	0.00	0.1	0.1	0.00
Hyperlipidemia	29.0	28.1	0.02	28.8	29.1	-0.01
Hypertensive disorder	38.0	37.1	0.02	37.8	38.1	-0.01
Lesion of liver	0.9	0.8	0.01	0.9	0.8	0.01
Lupus erythematosus	0.9	0.3	0.08	0.8	0.7	0.02
Obesity	8.9	8.9	0.00	8.9	9.0	0.00
Osteoarthritis	25.5	27.1	-0.04	25.8	25.1	0.02
Pneumonia	3.1	3.4	-0.01	3.2	3.2	0.00
Psoriasis	1.5	3.2	-0.11	1.7	2.0	-0.02
Renal impairment	5.3	4.8	0.02	5.2	5.4	-0.01
Rheumatoid arthritis	84.0	82.2	0.05	83.6	84.2	-0.02
Schizophrenia	0.1	0.1	0.00	0.1	0.1	0.00
Ulcerative colitis	0.3	1.2	-0.10	0.4	0.6	-0.03
Urinary tract infectious disease	6.0	5.2	0.04	5.8	5.5	0.02
Viral hepatitis C	1.0	1.0	0.00	1.0	0.9	0.01
Visual system disorder	8.6	8.8	0.00	8.6	8.5	0.00
Medical history: Cardiovascular disease						
Atrial fibrillation	3.3	3.1	0.01	3.2	3.2	0.00
Cerebrovascular disease	3.1	2.8	0.02	3.1	3.1	0.00
Coronary arteriosclerosis	5.7	5.6	0.00	5.7	5.6	0.00
Heart disease	15.9	14.6	0.04	15.6	15.6	0.00
Heart failure	2.6	2.3	0.02	2.6	2.4	0.01
Ischemic heart disease	1.7	1.6	0.01	1.7	1.5	0.02
Peripheral vascular disease	1.6	1.6	0.00	1.6	1.8	-0.02
Pulmonary embolism	0.8	0.7	0.01	0.8	0.8	0.00
Venous thrombosis	1.3	1.2	0.01	1.3	1.4	-0.01
Medical history: Neoplasms						
Hematologic neoplasm	0.4	0.3	0.02	0.4	0.4	0.01
Malignant lymphoma	0.4	0.5	-0.01	0.4	0.6	-0.03
Malignant neoplasm of anorectum	0.1	0.1	-0.01	0.1	0.1	-0.01
Malignant neoplastic disease	6.9	6.6	0.01	6.8	7.0	-0.01
Malignant tumor of breast	1.5	1.4	0.01	1.4	1.6	-0.01
Malignant tumor of colon	0.3	0.3	0.00	0.3	0.3	-0.01
Malignant tumor of lung	0.3	0.4	-0.02	0.3	0.3	-0.01
Malignant tumor of urinary bladder	0.2	0.3	-0.01	0.2	0.2	0.00
Primary malignant neoplasm of prostate	0.4	0.3	0.00	0.4	0.3	0.00
Medication use						
Agents acting on the renin-angiotensin system	33.2	33.6	-0.01	33.3	33.6	-0.01
Antibacterials for systemic use	24.7	25.3	-0.01	24.9	24.6	0.01
Antidepressants	36.1	34.9	0.02	35.8	35.7	0.00
Antiepileptics	24.0	24.1	0.00	24.0	24.0	0.00
Antiinflammatory and antirheumatic products	42.8	44.4	-0.03	43.1	43.5	-0.01
Antineoplastic agents	35.9	41.4	-0.11	37.3	37.6	-0.01
Antipsoriatics	0.6	0.7	0.00	0.6	0.7	0.00
Antithrombotic agents	25.2	23.5	0.04	24.9	25.2	-0.01
Beta blocking agents	25.2	25.1	0.00	25.2	25.8	-0.02

Calcium channel blockers	17.5	17.7	0.00	17.5	17.7	0.00
Diuretics	30.6	30.0	0.01	30.5	31.1	-0.01
Drugs for acid related disorders	41.6	41.6	0.00	41.6	42.1	-0.01
Drugs for obstructive airway diseases	30.9	30.0	0.02	30.8	31.0	0.00
Drugs used in diabetes	14.2	14.3	0.00	14.3	14.8	-0.01
Immunosuppressants	49.4	61.2	-0.24	52.2	52.0	0.00
Lipid modifying agents	33.2	33.7	-0.01	33.3	33.5	0.00
Opioids	28.4	30.7	-0.05	28.9	28.8	0.00
Psycholeptics	26.3	25.6	0.02	26.1	26.1	0.00
Psychostimulants, agents used for adhd and nootropics	4.0	3.8	0.01	4.0	4.0	0.00

7.2. CCAE

Characteristic	Before PS stratification			After PS stratification		
	HQ	SSZ	Std. diff	HQ	SSZ	Std. diff
Age group						
15-19	0.6	0.6	0.00	0.6	0.6	0.00
20-24	1.9	1.9	0.00	1.8	2.0	-0.01
25-29	2.6	2.6	0.00	2.5	2.7	-0.01
30-34	4.5	4.6	0.00	4.5	4.4	0.01
35-39	7.2	7.3	0.00	7.1	7.1	0.00
40-44	9.8	9.5	0.01	9.7	9.5	0.01
45-49	13.7	12.9	0.02	13.6	13.5	0.00
50-54	18.2	18.2	0.00	18.2	18.0	0.00
55-59	20.6	21.0	-0.01	20.8	20.8	0.00
60-64	19.0	19.7	-0.02	19.4	19.8	-0.01
65-69	1.8	1.7	0.01	1.8	1.6	0.01
Gender: female	82.0	74.3	0.19	80.1	79.7	0.01
Medical history: General						
Acute respiratory disease	35.5	34.3	0.02	35.1	34.8	0.01
Attention deficit hyperactivity disorder	1.5	1.5	0.00	1.5	1.5	0.00
Chronic liver disease	3.2	3.2	0.00	3.2	3.3	-0.01
Chronic obstructive lung disease	4.2	4.5	-0.01	4.3	4.5	-0.01
Crohn's disease	0.6	1.8	-0.12	0.7	1.1	-0.04
Dementia	0.2	0.2	0.01	0.2	0.2	0.00
Depressive disorder	13.4	13.5	0.00	13.3	13.5	-0.01
Diabetes mellitus	13.5	13.4	0.00	13.6	13.7	-0.01
Gastroesophageal reflux disease	13.7	13.5	0.01	13.6	13.6	0.00
Gastrointestinal hemorrhage	2.9	3.4	-0.03	3.0	3.2	-0.01
Human immunodeficiency virus infection	0.1	0.2	-0.01	0.1	0.1	0.00
Hyperlipidemia	31.5	30.6	0.02	31.2	31.4	0.00
Hypertensive disorder	34.7	34.9	0.00	34.7	35.1	-0.01
Lesion of liver	0.9	0.8	0.01	0.9	0.8	0.00
Lupus erythematosus	1.5	0.5	0.10	1.3	0.9	0.03
Obesity	9.3	9.1	0.00	9.2	9.4	-0.01
Osteoarthritis	43.4	44.3	-0.02	43.5	44.3	-0.01
Pneumonia	4.0	3.9	0.00	4.0	4.0	0.00
Psoriasis	3.0	8.9	-0.25	3.8	5.2	-0.07
Renal impairment	3.1	2.8	0.02	3.0	2.8	0.01
Rheumatoid arthritis	84.2	85.7	-0.04	84.9	85.3	-0.01
Schizophrenia	0.1	0.1	-0.01	0.1	0.1	-0.01
Ulcerative colitis	0.6	1.9	-0.12	0.7	1.0	-0.04
Urinary tract infectious disease	11.9	10.8	0.03	11.6	11.5	0.00
Viral hepatitis C	1.1	1.0	0.01	1.1	1.0	0.01
Visual system disorder	25.7	26.2	-0.01	25.7	25.8	0.00
Medical history: Cardiovascular disease						
Atrial fibrillation	1.4	1.3	0.02	1.4	1.3	0.01
Cerebrovascular disease	2.8	2.6	0.01	2.8	2.8	0.00
Coronary arteriosclerosis	4.4	4.6	-0.01	4.4	4.4	0.00
Heart disease	15.7	15.0	0.02	15.5	15.4	0.00
Heart failure	1.9	2.0	0.00	1.9	1.9	0.00
Ischemic heart disease	2.9	3.2	-0.01	3.0	3.1	-0.01
Peripheral vascular disease	1.6	1.5	0.01	1.5	1.6	0.00
Pulmonary embolism	0.8	0.6	0.03	0.8	0.6	0.02
Venous thrombosis	1.6	1.4	0.02	1.5	1.5	0.00
Medical history: Neoplasms						
Hematologic neoplasm	1.0	1.0	0.00	1.0	1.0	0.00
Malignant lymphoma	0.5	0.5	0.00	0.5	0.4	0.01
Malignant neoplasm of anorectum	0.1	0.1	0.00	0.1	0.1	0.00
Malignant neoplastic disease	6.5	6.5	0.00	6.5	6.5	0.00
Malignant tumor of breast	1.8	1.6	0.02	1.8	1.7	0.01
Malignant tumor of colon	0.2	0.2	0.00	0.2	0.2	0.00
Malignant tumor of lung	0.1	0.2	-0.01	0.2	0.1	0.00
Malignant tumor of urinary bladder	0.1	0.1	0.00	0.1	0.1	0.00
Primary malignant neoplasm of prostate	0.4	0.4	-0.01	0.4	0.4	0.00
Medication use						
Agents acting on the renin-angiotensin system	24.3	24.9	-0.01	24.5	24.7	0.00
Antibacterials for systemic use	43.8	44.3	-0.01	43.8	43.8	0.00
Antidepressants	36.4	36.4	0.00	36.3	36.5	0.00
Antiepileptics	20.3	21.0	-0.02	20.4	20.2	0.00
Antiinflammatory and antirheumatic products	55.3	57.3	-0.04	55.8	56.8	-0.02
Antineoplastic agents	30.7	37.9	-0.15	33.1	33.1	0.00
Antipsoratics	0.7	1.3	-0.06	0.7	1.0	-0.03
Antithrombotic agents	7.4	7.3	0.01	7.4	7.3	0.00
Beta blocking agents	15.7	16.2	-0.01	15.9	16.2	-0.01
Calcium channel blockers	11.7	11.5	0.01	11.7	11.8	0.00
Diuretics	24.4	24.3	0.00	24.5	24.5	0.00
Drugs for acid related disorders	32.3	33.6	-0.03	32.6	32.6	0.00
Drugs for obstructive airway diseases	29.7	29.3	0.01	29.5	29.5	0.00
Drugs used in diabetes	10.4	10.5	0.00	10.5	10.8	-0.01
Immunosuppressants	39.6	53.1	-0.27	43.4	43.6	0.00
Lipid modifying agents	22.6	23.5	-0.02	22.8	23.2	-0.01
Opioids	38.5	40.8	-0.05	39.0	39.3	-0.01
Psycholeptics	33.6	33.7	0.00	33.4	33.3	0.00
Psychostimulants, agents used for adhd and nootropics	5.9	5.7	0.01	5.8	5.7	0.01

7.3. Clininformatics

Characteristic	Before PS stratification			After PS stratification		
	HCO	SSZ	Std. diff	HCO	SSZ	Std. diff
Age group						
15-19	0.3	0.4	-0.01	0.3	0.4	-0.02
20-24	1.1	1.2	-0.01	1.1	1.1	-0.01
25-29	1.8	2.0	-0.01	1.8	1.8	-0.01
30-34	3.4	3.2	0.01	3.3	3.3	0.00
35-39	4.9	5.2	-0.01	4.9	4.8	0.00
40-44	6.9	6.7	0.01	6.8	6.4	0.01
45-49	8.9	9.1	0.00	8.9	8.9	0.00
50-54	11.6	11.6	0.00	11.6	11.6	0.00
55-59	12.5	13.3	-0.02	12.7	12.9	-0.01
60-64	11.6	12.7	-0.03	11.9	12.0	0.00
65-69	11.3	12.2	-0.03	11.6	11.7	0.00
70-74	10.8	10.5	0.01	10.9	10.6	0.01
75-79	7.9	6.9	0.04	7.7	7.7	0.00
80-84	5.0	3.8	0.06	4.8	4.9	-0.01
85-89	1.9	1.3	0.05	1.8	1.7	0.01
90-94	0.0	0.0	0.03	0.0	0.0	0.03
Gender: female	79.5	72.1	0.17	77.6	77.6	0.00
Medical history: General						
Acute respiratory disease	34.6	33.4	0.02	34.2	34.2	0.00
Attention deficit hyperactivity disorder	1.2	1.1	0.00	1.2	1.1	0.00
Chronic liver disease	3.7	3.8	0.00	3.7	3.8	-0.01
Chronic obstructive lung disease	11.2	10.9	0.01	11.2	11.2	0.00
Crohn's disease	0.7	2.4	-0.14	0.9	1.4	-0.05
Dementia	1.3	1.2	0.01	1.2	1.5	-0.02
Depressive disorder	18.5	18.2	0.01	18.4	18.3	0.00
Diabetes mellitus	20.8	20.3	0.01	20.7	21.0	-0.01
Gastroesophageal reflux disease	21.6	21.2	0.01	21.5	21.7	-0.01
Gastrointestinal hemorrhage	4.0	4.5	-0.02	4.0	4.0	0.00
Human immunodeficiency virus infection	0.2	0.2	-0.01	0.2	0.2	-0.01
Hyperlipidemia	46.7	45.5	0.02	46.4	47.1	-0.01
Hypertensive disorder	51.3	51.1	0.00	51.3	51.7	-0.01
Lesion of liver	1.3	1.2	0.01	1.3	1.2	0.00
Lupus erythematosus	1.7	0.7	0.10	1.5	1.1	0.03
Obesity	12.1	12.6	-0.01	12.2	12.2	0.00
Osteoarthritis	56.3	55.5	0.02	56.1	56.7	-0.01
Pneumonia	6.5	5.8	0.03	6.3	6.4	0.00
Psoriasis	3.1	8.1	-0.22	3.8	4.9	-0.05
Renal impairment	9.9	9.3	0.02	9.7	9.9	-0.01
Rheumatoid arthritis	84.3	85.4	-0.03	84.8	85.1	-0.01
Schizophrenia	0.2	0.1	0.01	0.2	0.1	0.01
Ulcerative colitis	0.7	2.3	-0.13	0.8	1.3	-0.04
Urinary tract infectious disease	15.9	13.6	0.06	15.3	15.4	0.00
Viral hepatitis C	1.5	1.7	-0.02	1.5	1.7	-0.02
Visual system disorder	40.2	40.1	0.00	40.0	39.6	0.01
Medical history: Cardiovascular disease						
Atrial fibrillation	5.0	4.2	0.04	4.8	4.7	0.00
Cerebrovascular disease	6.3	5.6	0.03	6.1	6.0	0.00
Coronary arteriosclerosis	10.8	10.5	0.01	10.7	10.9	-0.01
Heart disease	27.7	26.1	0.04	27.3	27.8	-0.01
Heart failure	6.3	5.8	0.02	6.1	6.4	-0.01
Ischemic heart disease	6.5	6.3	0.01	6.5	6.6	-0.01
Peripheral vascular disease	4.7	4.3	0.02	4.7	4.6	0.00
Pulmonary embolism	1.2	0.9	0.03	1.2	1.1	0.01
Venous thrombosis	2.3	2.1	0.02	2.2	2.4	-0.01
Medical history: Neoplasms						
Hematologic neoplasm	1.4	1.2	0.02	1.4	1.3	0.01
Malignant lymphoma	0.7	0.7	-0.01	0.7	0.8	-0.01
Malignant neoplasm of anorectum	0.2	0.3	-0.02	0.2	0.2	-0.01
Malignant neoplastic disease	10.4	10.4	0.00	10.4	10.6	-0.01
Malignant tumor of breast	2.5	2.0	0.03	2.4	2.4	0.00
Malignant tumor of colon	0.4	0.5	-0.01	0.4	0.5	-0.01
Malignant tumor of lung	0.4	0.4	0.01	0.4	0.4	0.01
Malignant tumor of urinary bladder	0.3	0.4	-0.01	0.3	0.3	0.00
Primary malignant neoplasm of prostate	1.0	1.2	-0.02	1.0	1.0	0.00
Medication use						
Agents acting on the renin-angiotensin system	32.3	32.7	-0.01	32.4	32.6	0.00
Antibacterials for systemic use	41.2	42.1	-0.02	41.3	41.2	0.00
Antidepressants	35.0	35.4	-0.01	35.0	35.0	0.00
Antiepileptics	22.1	22.8	-0.02	22.2	22.1	0.00
Antiinflammatory and antirheumatic products	48.0	50.0	-0.04	48.5	49.1	-0.01
Antineoplastic agents	30.1	37.9	-0.17	32.6	32.2	0.01
Antipsoratics	0.8	1.1	-0.03	0.9	0.9	0.00
Antithrombotic agents	11.8	10.7	0.04	11.5	11.4	0.00
Beta blocking agents	23.2	22.5	0.02	23.1	23.1	0.00
Calcium channel blockers	17.8	16.7	0.03	17.6	17.7	0.00
Diuretics	30.3	29.0	0.03	30.0	30.5	-0.01
Drugs for acid related disorders	33.6	34.6	-0.02	33.8	34.4	-0.01
Drugs for obstructive airway diseases	29.3	29.2	0.00	29.2	29.5	-0.01
Drugs used in diabetes	14.1	14.2	0.00	14.1	14.5	-0.01
Immunosuppressants	39.0	52.6	-0.28	43.0	42.2	0.02
Lipid modifying agents	31.9	32.2	-0.01	32.0	32.7	-0.01
Opioids	38.4	40.2	-0.04	38.8	38.8	0.00

Psycholeptics	30.4	29.4	0.02	30.1	29.9	0.00
Psychostimulants, agents used for adhd and nootropics	4.0	3.7	0.02	4.0	3.7	0.02

7.4. CPRD

	Before PS stratification			After PS stratification		
	HCQ	SSZ	Std. diff	HCQ	SSZ	Std. diff
Characteristic						
Age group	%	%		%	%	
15-19	0.3	0.2	0.01	0.3	0.2	0.00
20-24	0.8	1.0	-0.02	0.8	0.9	-0.01
25-29	1.3	1.6	-0.03	1.4	1.6	-0.02
30-34	2.7	3.1	-0.02	2.9	3.0	0.00
35-39	4.5	4.6	0.00	4.7	4.5	0.01
40-44	5.6	6.6	-0.04	6.3	6.4	0.00
45-49	8.9	8.0	0.03	8.5	8.5	0.00
50-54	11.3	10.9	0.02	11.3	11.0	0.01
55-59	13.2	12.6	0.02	13.4	12.8	0.02
60-64	13.1	13.2	0.00	12.9	13.0	0.00
65-69	12.7	12.7	0.00	12.6	12.7	0.00
70-74	10.9	11.6	-0.02	11.1	11.2	0.00
75-79	8.3	8.1	0.01	8.0	8.0	0.00
80-84	4.5	4.3	0.01	4.2	4.4	-0.01
85-89	1.6	1.3	0.03	1.3	1.5	-0.01
90-94	0.3	0.2	0.03	0.3	0.2	0.01
Gender: female	72.8	67.9	0.11	70.0	70.2	0.00
Medical history: General						
Acute respiratory disease	9.2	9.1	0.00	9.4	9.3	0.01
Chronic liver disease	0.1	0.1	0.00	0.1	0.0	0.01
Chronic obstructive lung disease	2.3	2.0	0.02	2.2	2.0	0.01
Crohn's disease	<0.1	0.1	-0.03	0.1	0.1	-0.02
Dementia	0.2	0.0	0.06	0.2	0.0	0.05
Depressive disorder	2.7	3.2	-0.03	3.1	3.1	0.00
Diabetes mellitus	2.2	2.1	0.01	2.1	2.2	0.00
Gastroesophageal reflux disease	0.5	0.4	0.02	0.4	0.4	0.01
Gastrointestinal hemorrhage	1.0	1.4	-0.03	1.1	1.4	-0.02
Hyperlipidemia	1.2	1.0	0.02	1.2	1.0	0.01
Hypertensive disorder	3.0	4.0	-0.05	3.2	3.6	-0.02
Lesion of liver	0.1	0.1	0.01	0.1	0.1	0.01
Lupus erythematosus	0.2	0.0	0.05	0.2	0.0	0.07
Obesity	0.4	0.5	-0.01	0.4	0.5	-0.01
Osteoarthritis	7.7	10.4	-0.09	8.6	8.9	-0.01
Pneumonia	0.8	0.6	0.03	0.9	0.6	0.03
Psoriasis	0.8	1.9	-0.10	1.2	1.5	-0.02
Renal impairment	2.3	1.8	0.04	1.9	2.2	-0.02
Rheumatoid arthritis	61.5	72.2	-0.23	67.2	66.2	0.02
Schizophrenia	<0.1	0.0	0.00	0.0	0.0	0.00
Ulcerative colitis	<0.1	0.1	-0.03	0.0	0.1	-0.03
Urinary tract infectious disease	3.3	3.1	0.01	3.2	3.2	0.00
Viral hepatitis C	<0.1	0.0	0.00	0.0	0.0	0.00
Visual system disorder	6.9	6.9	0.00	6.7	7.0	-0.01
Medical history: Cardiovascular disease						
Atrial fibrillation	0.7	0.7	0.00	0.8	0.7	0.02
Cerebrovascular disease	0.4	0.8	-0.05	0.5	0.7	-0.03
Coronary arteriosclerosis	0.1	0.1	0.00	0.1	0.1	0.00
Heart disease	3.0	3.3	-0.02	3.3	3.1	0.02
Heart failure	0.5	0.7	-0.02	0.7	0.6	0.01
Ischemic heart disease	1.0	1.5	-0.04	1.2	1.3	-0.01
Peripheral vascular disease	0.2	0.2	0.01	0.3	0.2	0.02
Pulmonary embolism	0.2	0.2	-0.01	0.2	0.3	-0.02
Venous thrombosis	0.8	1.0	-0.01	0.9	1.0	-0.01
Medical history: Neoplasms						
Hematologic neoplasm	0.1	0.0	0.01	0.1	0.0	0.01
Malignant lymphoma	<0.1	0.0	0.00	0.0	0.0	0.00
Malignant neoplastic disease	1.3	1.0	0.02	1.2	1.0	0.02
Malignant tumor of breast	0.1	0.1	0.00	0.1	0.1	-0.01
Malignant tumor of colon	0.1	0.0	0.01	0.0	0.0	0.00
Malignant tumor of lung	0.1	0.0	0.02	0.1	0.0	0.02
Medication use						
Agents acting on the renin-angiotensin system	22.1	16.7	0.14	19.3	19.3	0.00
Antibacterials for systemic use	37.3	35.0	0.05	35.9	36.3	-0.01
Antidepressants	26.6	22.6	0.09	24.9	24.9	0.00
Antiepileptics	6.5	4.3	0.10	5.5	5.2	0.01
Antiinflammatory and antirheumatic products	60.5	67.7	-0.15	64.3	64.0	0.01
Antineoplastic agents	51.5	28.5	0.48	39.3	40.8	-0.03
Antipsoratics	0.7	1.3	-0.06	0.9	1.2	-0.02
Antithrombotic agents	17.9	16.6	0.03	17.2	17.1	0.00
Beta blocking agents	14.4	13.4	0.03	14.3	13.7	0.02
Calcium channel blockers	15.6	12.0	0.10	13.4	13.4	0.00
Diuretics	19.1	20.8	-0.04	20.0	20.0	0.00
Drugs for acid related disorders	58.3	51.0	0.15	54.1	54.6	-0.01
Drugs for obstructive airway diseases	22.5	18.9	0.09	20.1	20.1	0.00
Drugs used in diabetes	7.1	5.8	0.05	6.1	6.5	-0.02
Immunosuppressants	55.3	29.8	0.53	42.2	43.1	-0.02
Lipid modifying agents	23.0	17.1	0.15	19.4	19.7	-0.01
Opioids	36.3	41.1	-0.10	39.1	38.8	0.01
Psycholeptics	16.5	16.4	0.00	16.6	16.5	0.00
Psychostimulants, agents used for adhd and nootropics	0.1	0.1	0.01	0.1	0.1	0.01

7.5. DAGermany

	Before PS stratification			After PS stratification		
	HCQ	SSZ	Std. diff.	HCQ	SSZ	Std. diff.
Characteristic						
Age group		%	%		%	
15-19	0.3	0.5	-0.03	0.3	0.5	-0.04
20-24	1.1	1.3	-0.02	1.1	1.2	-0.01
25-29	1.9	2.4	-0.04	2.1	2.4	-0.02
30-34	2.3	3.6	-0.07	3.0	3.0	0.00
35-39	4.0	4.1	-0.01	3.9	4.1	-0.01
40-44	5.7	6.6	-0.04	6.0	6.2	-0.01
45-49	8.5	9.2	-0.03	8.9	9.1	-0.01
50-54	12.0	12.6	-0.02	12.7	12.4	0.01
55-59	14.2	14.8	-0.02	14.6	15.0	-0.01
60-64	13.3	12.1	0.04	12.3	12.4	0.00
65-69	11.5	10.7	0.02	11.3	10.7	0.02
70-74	10.3	9.5	0.03	9.8	9.7	0.00
75-79	9.0	7.4	0.06	8.2	8.0	0.00
80-84	4.5	3.9	0.03	4.3	4.0	0.02
85-89	1.4	1.0	0.04	1.3	1.0	0.03
90-94	0.2	0.2	0.00	0.2	0.2	0.00
Gender: female	81.4	72.7	0.21	76.2	77.2	-0.02
Medical history: General						
Acute respiratory disease	11.9	12.5	-0.02	12.2	11.8	0.01
Attention deficit hyperactivity disorder	<0.1	0.1	-0.01	0.1	<0.1	0.02
Chronic liver disease	0.6	0.3	0.05	0.6	0.3	0.05
Chronic obstructive lung disease	3.4	3.9	-0.03	3.3	3.7	-0.02
Crohn's disease	0.2	1.4	-0.14	0.4	1.0	-0.07
Dementia	0.6	0.5	0.01	0.6	0.5	0.01
Depressive disorder	7.5	7.7	-0.01	7.6	7.5	0.01
Diabetes mellitus	6.4	7.1	-0.03	6.9	6.6	0.01
Gastroesophageal reflux disease	1.9	2.0	0.00	1.8	1.9	-0.01
Gastrointestinal hemorrhage	0.5	0.6	-0.02	0.5	0.6	-0.02
Hyperlipidemia	7.1	8.3	-0.04	7.9	7.6	0.01
Hypertensive disorder	18.5	19.1	-0.02	18.9	18.2	0.02
Lesion of liver	0.5	0.3	0.03	0.4	0.3	0.03
Lupus erythematosus	0.3	<0.1	0.07	0.2	<0.1	0.06
Obesity	2.2	2.5	-0.02	2.2	2.4	-0.01
Osteoarthritis	11.5	13.3	-0.06	12.4	12.2	0.01
Pneumonia	1.9	1.4	0.04	2.0	1.5	0.03
Psoriasis	2.3	4.5	-0.12	3.6	3.5	0.00
Renal impairment	2.7	2.2	0.03	2.5	2.4	0.01
Rheumatoid arthritis	46.1	54.6	-0.17	52.1	49.9	0.04
Schizophrenia	<0.1	0.1	-0.03	<0.1	0.1	-0.01
Ulcerative colitis	0.2	1.6	-0.16	0.4	1.1	-0.09
Urinary tract infectious disease	4.0	4.0	0.00	4.0	3.9	0.00
Viral hepatitis C	0.3	0.1	0.04	0.3	0.1	0.04
Visual system disorder	5.7	5.5	0.01	5.4	5.4	0.00
Medical history: Cardiovascular disease						
Atrial fibrillation	0.8	0.8	0.00	0.8	0.8	0.00
Cerebrovascular disease	1.4	1.7	-0.03	1.4	1.6	-0.02
Coronary arteriosclerosis	1.0	1.1	-0.01	1.0	1.2	-0.02
Heart disease	10.5	11.4	-0.03	10.5	10.7	0.00
Heart failure	2.0	2.6	-0.04	2.0	2.4	-0.03
Ischemic heart disease	4.4	5.1	-0.04	4.6	4.5	0.00
Peripheral vascular disease	1.3	1.0	0.02	1.2	0.9	0.02
Pulmonary embolism	0.6	0.3	0.04	0.6	0.4	0.03
Venous thrombosis	1.2	1.4	-0.02	1.4	1.5	0.00
Medical history: Neoplasms						
Hematologic neoplasm	0.3	0.2	0.03	0.3	0.2	0.02
Malignant lymphoma	0.2	0.2	0.01	0.2	0.1	0.01
Malignant neoplasm of anorectum	0.2	0.2	0.02	0.2	0.2	0.00
Malignant neoplastic disease	3.3	3.2	0.00	3.2	3.2	0.00
Malignant tumor of breast	0.7	0.6	0.00	0.6	0.6	0.00
Malignant tumor of colon	0.3	0.1	0.03	0.3	0.1	0.04
Malignant tumor of lung	<0.1	<0.1	0.02	<0.1	<0.1	0.00
Malignant tumor of urinary bladder	<0.1	0.2	-0.05	<0.1	0.2	-0.05
Primary malignant neoplasm of prostate	0.2	0.3	-0.03	0.2	0.3	-0.02
Medication use						
Agents acting on the renin-angiotensin system	16.7	17.0	-0.01	16.9	16.5	0.01
Antibacterials for systemic use	12.7	14.6	-0.06	13.4	13.6	-0.01
Antidepressants	8.8	7.7	0.04	8.1	8.0	0.00
Antiepileptics	3.0	2.3	0.05	2.6	2.3	0.02
Antiinflammatory and antirheumatic products	33.1	35.9	-0.06	35.3	34.6	0.02
Antineoplastic agents	31.5	26.7	0.10	29.2	30.3	-0.02
Antipsoriatics	0.3	0.3	0.00	0.3	0.2	0.00
Antithrombotic agents	10.0	9.9	0.00	9.6	9.3	0.01
Beta blocking agents	13.7	13.2	0.02	12.8	13.0	0.00
Calcium channel blockers	7.5	7.7	-0.01	7.4	7.3	0.00
Diuretics	13.9	14.5	-0.02	14.3	13.6	0.02
Drugs for acid related disorders	32.0	32.5	-0.01	32.1	32.4	-0.01
Drugs for obstructive airway diseases	6.9	7.7	-0.03	7.2	7.2	0.00
Drugs used in diabetes	4.4	4.8	-0.02	4.7	4.6	0.01
Immunosuppressants	40.3	35.0	0.11	38.7	38.4	0.00
Lipid modifying agents	7.3	9.1	-0.06	8.0	8.1	0.00
Opioids	12.3	12.9	-0.02	12.2	12.2	0.00
Psycholeptics	4.8	5.9	-0.05	4.8	5.3	-0.02

Psychostimulants, agents used for adhd and nootropics		0.2	0.4	-0.03	0.2	0.3	-0.03
---	--	-----	-----	-------	-----	-----	-------

7.6. IMRD

	Before PS stratification			After PS stratification		
	HCQ	SSZ	Std. diff.	HCQ	SSZ	Std. diff.
Characteristic	%	%		%	%	
Age group						
15-19	0.2	0.2	0.02	0.2	0.2	0.01
20-24	0.8	1.0	-0.03	0.8	1.0	-0.02
25-29	1.2	1.6	-0.03	1.4	1.6	-0.02
30-34	2.8	3.2	-0.02	2.9	3.1	-0.01
35-39	4.8	5.0	-0.01	5.0	4.8	0.01
40-44	6.0	6.1	0.00	6.3	6.0	0.01
45-49	8.7	7.8	0.03	8.4	8.5	0.00
50-54	11.3	10.8	0.02	11.2	11.0	0.01
55-59	13.0	12.4	0.02	12.7	12.4	0.01
60-64	13.2	13.8	-0.02	13.4	13.5	0.00
65-69	13.0	12.8	0.01	12.9	13.0	0.00
70-74	11.0	11.4	-0.01	11.3	11.2	0.00
75-79	7.7	8.3	-0.02	7.8	7.9	0.00
80-84	4.4	4.1	0.02	4.1	4.2	0.00
85-89	1.5	1.3	0.02	1.3	1.4	-0.01
90-94	0.3	0.2	0.02	0.2	0.2	0.00
Gender: female	73.2	68.0	0.11	70.7	71.0	0.00
Race						
race = Asian	0.1	0.1	0.02	0.1	0.1	0.00
race = White	29.8	25.8	0.09	27.4	27.6	0.00
race = Asian Indian	0.7	0.4	0.04	0.6	0.5	0.02
race = Bangladeshi	0.1	<0.1	0.02	<0.1	<0.1	0.02
race = Chinese	0.1	<0.1	0.03	0.1	<0.1	0.03
race = Pakistani	0.3	0.2	0.03	0.3	0.2	0.03
race = Black	0.4	0.2	0.03	0.3	0.2	0.02
race = African	0.2	<0.1	0.05	0.2	<0.1	0.04
race = European	0.1	<0.1	0.02	0.1	<0.1	0.02
Medical history: General						
Acute respiratory disease	9.2	9.3	0.00	9.2	9.1	0.00
Chronic liver disease	0.1	0.1	0.00	<0.1	<0.1	0.00
Chronic obstructive lung disease	2.1	2.5	-0.02	2.2	2.3	-0.01
Crohn's disease	<0.1	0.2	-0.05	<0.1	0.1	-0.04
Dementia	0.2	0.1	0.03	0.1	0.1	0.02
Depressive disorder	2.6	2.9	-0.02	2.9	2.7	0.01
Diabetes mellitus	2.3	2.2	0.01	2.2	2.1	0.01
Gastroesophageal reflux disease	0.3	0.6	-0.03	0.4	0.6	-0.03
Gastrointestinal hemorrhage	0.9	1.3	-0.04	1.0	1.1	-0.01
Hyperlipidemia	1.1	1.3	-0.02	1.1	1.2	-0.01
Hypertensive disorder	3.1	3.7	-0.03	3.2	3.2	0.00
Lesion of liver	0.1	0.1	0.01	0.1	<0.1	0.01
Lupus erythematosus	0.1	0.0		0.1	0.0	
Obesity	0.3	0.5	-0.03	0.4	0.6	-0.03
Osteoarthritis	7.5	9.4	-0.07	8.1	8.1	0.00
Pneumonia	0.7	0.6	0.00	0.7	0.7	0.00
Psoriasis	0.8	2.2	-0.12	1.3	1.6	-0.02
Renal impairment	2.5	2.2	0.01	2.3	2.3	0.00
Rheumatoid arthritis	61.4	69.3	-0.17	65.7	63.7	0.04
Schizophrenia	<0.1	<0.1	0.01	<0.1	<0.1	0.02
Ulcerative colitis	<0.1	<0.1	-0.01	<0.1	<0.1	-0.01
Urinary tract infectious disease	3.1	2.9	0.01	3.1	3.0	0.01
Visual system disorder	6.6	7.0	-0.02	6.6	6.8	-0.01
Medical history: Cardiovascular disease						
Atrial fibrillation	0.7	0.7	0.00	0.7	0.6	0.01
Cerebrovascular disease	0.5	0.7	-0.03	0.5	0.7	-0.02
Coronary arteriosclerosis	0.1	0.1	0.01	0.1	0.1	0.02
Heart disease	2.7	2.9	-0.01	2.8	2.6	0.02
Heart failure	0.4	0.4	-0.01	0.5	0.4	0.01
Ischemic heart disease	0.8	1.2	-0.04	1.0	1.0	0.00
Peripheral vascular disease	0.2	0.2	0.01	0.3	0.2	0.02
Pulmonary embolism	0.2	0.2	-0.01	0.2	0.3	-0.02
Venous thrombosis	0.8	1.1	-0.03	0.8	1.0	-0.02
Medical history: Neoplasms						
Hematologic neoplasm	0.1	0.1	0.01	0.1	<0.1	0.02
Malignant lymphoma	<0.1	<0.1	-0.01	<0.1	<0.1	0.00
Malignant neoplasm of anorectum	<0.1	<0.1	0.02	<0.1	<0.1	0.02
Malignant neoplastic disease	1.3	1.1	0.02	1.2	1.0	0.02
Malignant tumor of breast	0.2	0.2	0.02	0.2	0.2	0.01
Malignant tumor of colon	<0.1	<0.1	-0.01	<0.1	<0.1	0.00
Malignant tumor of lung	0.1	0.1	0.01	0.1	0.1	0.02
Medication use						
Agents acting on the renin-angiotensin system	0.6	0.6	0.00	0.6	0.8	-0.02
Antibacterials for systemic use	3.8	3.4	0.02	3.6	3.5	0.01
Antidepressants	1.1	1.1	-0.01	1.0	1.2	-0.02
Antiepileptics	0.1	0.2	-0.03	0.1	0.2	-0.03
Antiinflammatory and antirheumatic products	1.6	1.9	-0.03	1.7	1.7	-0.01
Antineoplastic agents	1.5	0.6	0.08	1.2	0.9	0.02
Antithrombotic agents	1.1	1.1	0.00	1.2	1.2	0.00
Beta blocking agents	0.4	0.6	-0.02	0.5	0.6	-0.01
Calcium channel blockers	0.6	0.5	0.00	0.6	0.5	0.02
Diuretics	0.8	1.0	-0.02	1.0	0.9	0.01
Drugs for acid related disorders	1.6	1.7	0.00	1.7	1.6	0.01
Drugs for obstructive airway diseases	0.4	0.4	0.00	0.5	0.4	0.00

Drugs used in diabetes	0.2	0.2	0.01	0.2	0.2	0.00
Immunosuppressants	1.6	0.7	0.08	1.3	1.0	0.02
Lipid modifying agents	0.9	0.9	0.00	0.9	1.0	-0.01
Opioids	0.6	0.6	-0.01	0.6	0.6	-0.01
Psycholeptics	0.4	0.5	-0.01	0.4	0.4	0.00

7.7. MDCD

	Before PS stratification			After PS stratification		
	HCQ	SSZ	Std. diff	HCQ	SSZ	Std. diff
Characteristic						
Age group		%	%		%	
15-19	1.2	1.3	-0.01	1.2	1.5	-0.02
20-24	2.2	2.7	-0.04	2.1	3.3	-0.07
25-29	4.3	4.2	0.01	4.2	4.6	-0.02
30-34	6.7	6.6	0.00	6.5	6.6	0.00
35-39	9.0	8.8	0.01	8.7	9.0	-0.01
40-44	10.2	9.1	0.04	10.1	9.0	0.04
45-49	13.3	12.8	0.02	13.3	13.7	-0.01
50-54	15.9	16.2	-0.01	16.2	15.8	0.01
55-59	15.7	16.3	-0.01	16.0	15.2	0.02
60-64	12.0	13.7	-0.05	12.2	12.9	-0.02
65-69	4.5	4.0	0.02	4.6	4.1	0.02
70-74	2.0	2.0	-0.01	2.0	1.8	0.01
75-79	1.6	1.0	0.05	1.6	1.1	0.05
80-84	1.0	0.9	0.01	1.0	0.9	0.01
85-89	0.4	0.2	0.03	0.4	0.3	0.00
Gender: female	86.0	79.1	0.18	84.4	84.3	0.00
Race						
race = Black or African American	28.7	25.2	0.08	28.0	26.3	0.04
race = White	54.4	57.1	-0.05	55.1	55.3	-0.01
Ethnicity						
ethnicity = Hispanic or Latino	2.4	1.9	0.03	2.4	2.1	0.02
Medical history: General						
Acute respiratory disease	41.9	40.2	0.03	41.6	41.4	0.00
Attention deficit hyperactivity disorder	2.6	2.0	0.04	2.6	2.5	0.00
Chronic liver disease	6.9	7.4	-0.02	6.9	7.1	-0.01
Chronic obstructive lung disease	21.1	21.5	-0.01	21.2	21.0	0.00
Crohn's disease	0.8	3.4	-0.18	1.0	1.8	-0.07
Dementia	1.2	0.9	0.03	1.1	1.1	0.00
Depressive disorder	36.0	35.3	0.02	35.4	36.2	-0.02
Diabetes mellitus	25.5	25.6	0.00	25.5	25.5	0.00
Gastroesophageal reflux disease	29.6	30.4	-0.02	29.5	30.4	-0.02
Gastrointestinal hemorrhage	5.0	6.3	-0.06	5.0	6.0	-0.04
Human immunodeficiency virus infection	0.5	0.8	-0.04	0.5	0.8	-0.04
Hyperlipidemia	36.4	36.9	-0.01	36.3	37.7	-0.03
Hypertensive disorder	55.6	53.3	0.05	55.2	54.3	0.02
Lesion of liver	2.0	2.0	0.00	2.0	2.0	0.00
Lupus erythematosus	3.0	1.2	0.13	2.8	1.8	0.07
Obesity	21.4	20.3	0.03	21.2	20.6	0.01
Osteoarthritis	57.2	56.7	0.01	57.3	57.4	0.00
Pneumonia	8.7	8.1	0.02	8.4	7.9	0.02
Psoriasis	2.0	6.4	-0.22	2.5	3.4	-0.05
Renal impairment	9.4	8.0	0.05	9.2	8.3	0.03
Rheumatoid arthritis	80.7	84.9	-0.11	81.9	83.2	-0.03
Schizophrenia	1.7	2.0	-0.02	1.6	2.1	-0.03
Ulcerative colitis	0.5	1.6	-0.11	0.6	1.3	-0.07
Urinary tract infectious disease	17.8	16.6	0.03	17.3	16.7	0.02
Viral hepatitis C	5.9	6.0	-0.01	5.9	6.2	-0.02
Visual system disorder	40.0	40.5	-0.01	40.0	39.5	0.01
Medical history: Cardiovascular disease						
Atrial fibrillation	3.3	2.5	0.05	3.2	3.2	0.00
Cerebrovascular disease	5.3	5.3	0.00	5.1	5.6	-0.02
Coronary arteriosclerosis	9.8	8.6	0.04	9.6	9.4	0.01
Heart disease	29.6	27.2	0.05	29.0	27.9	0.02
Heart failure	8.7	7.5	0.04	8.4	8.0	0.01
Ischemic heart disease	7.3	7.0	0.01	7.1	7.4	-0.01
Peripheral vascular disease	4.8	4.2	0.03	4.6	4.2	0.02
Pulmonary embolism	2.0	1.1	0.08	1.9	1.6	0.02
Venous thrombosis	3.1	2.5	0.03	2.9	3.3	-0.02
Medical history: Neoplasms						
Hematologic neoplasm	1.5	1.2	0.03	1.4	1.2	0.02
Malignant lymphoma	0.4	0.5	-0.01	0.4	0.4	0.01
Malignant neoplasm of anorectum	0.2	0.2	-0.01	0.2	<0.2	0.00
Malignant neoplastic disease	7.2	7.5	-0.01	7.0	7.3	-0.01
Malignant tumor of breast	2.0	1.7	0.02	1.9	1.5	0.03
Malignant tumor of colon	0.4	0.3	0.01	0.4	0.3	0.02
Malignant tumor of lung	0.4	0.3	0.03	0.4	0.3	0.01
Malignant tumor of urinary bladder	0.2	<0.2	0.01	0.2	<0.2	0.02
Primary malignant neoplasm of prostate	0.2	0.2	-0.01	0.2	<0.2	0.01
Medication use						
Agents acting on the renin-angiotensin system	32.6	32.2	0.01	32.6	33.2	-0.01
Antibacterials for systemic use	50.4	48.6	0.04	50.1	48.0	0.04
Antidepressants	53.7	52.7	0.02	53.5	53.2	0.00
Antiepileptics	43.0	41.6	0.03	42.6	42.7	0.00
Antiinflammatory and antirheumatic products	58.3	59.8	-0.03	58.4	59.7	-0.03
Antineoplastic agents	30.3	42.0	-0.25	34.1	31.5	0.05
Antipsoriatics	0.8	0.7	0.02	0.8	0.6	0.03
Antithrombotic agents	18.8	17.0	0.04	18.5	17.7	0.02
Beta blocking agents	24.9	22.8	0.05	24.5	23.0	0.04
Calcium channel blockers	20.0	19.5	0.01	19.6	20.3	-0.02
Diuretics	33.7	32.3	0.03	33.3	32.0	0.03
Drugs for acid related disorders	50.1	50.7	-0.01	50.3	48.1	0.04
Drugs for obstructive airway diseases	46.3	46.5	0.00	46.1	46.7	-0.01

Drugs used in diabetes	18.4	19.8	-0.03	18.5	19.4	-0.02
Immunosuppressants	39.5	56.5	-0.35	44.5	40.8	0.07
Lipid modifying agents	29.1	30.1	-0.02	29.2	30.6	-0.03
Opioids	62.1	62.5	-0.01	62.0	62.7	-0.02
Psycholeptics	49.8	49.5	0.00	49.3	50.2	-0.02
Psychostimulants, agents used for adhd and nootropics	7.3	6.8	0.02	7.2	7.4	-0.01

7.8. MDCR

	Before PS stratification			After PS stratification		
	HCQ	SSZ	Std. diff.	HCQ	SSZ	Std. diff.
Characteristic						
Age group	%	%		%	%	
45-49	0.1	<0.1	0.01	0.1	<0.1	0.01
50-54	0.3	0.3	-0.01	0.3	0.3	0.00
55-59	0.7	1.0	-0.03	0.7	0.9	-0.01
60-64	1.7	2.0	-0.02	1.8	1.9	-0.01
65-69	23.7	26.4	-0.06	24.4	24.5	0.00
70-74	28.1	30.8	-0.06	28.6	28.7	0.00
75-79	22.6	20.5	0.05	22.2	21.9	0.01
80-84	14.6	13.3	0.04	14.3	14.2	0.00
85-89	6.8	4.3	0.11	6.2	6.2	0.00
90-94	1.3	1.2	0.01	1.3	1.3	0.00
95-99	0.1	0.1	0.01	0.1	0.1	0.01
00-04	0.0	<0.1	-0.01	0.0	<0.1	-0.02
Gender: female	73.0	68.5	0.10	71.7	71.6	0.00
Medical history: General						
Acute respiratory disease	27.5	26.5	0.02	27.3	27.3	0.00
Attention deficit hyperactivity disorder	0.2	0.2	0.00	0.2	0.2	0.00
Chronic liver disease	2.1	1.9	0.02	2.1	1.9	0.02
Chronic obstructive lung disease	15.7	16.2	-0.01	15.7	16.2	-0.01
Crohn's disease	0.5	1.3	-0.08	0.6	1.1	-0.05
Dementia	2.0	1.7	0.02	2.0	1.8	0.01
Depressive disorder	9.2	9.2	0.00	9.2	9.3	0.00
Diabetes mellitus	23.1	22.5	0.02	22.9	22.7	0.01
Gastroesophageal reflux disease	16.5	16.5	0.00	16.2	16.5	-0.01
Gastrointestinal hemorrhage	4.8	5.1	-0.01	4.8	4.9	0.00
Human immunodeficiency virus infection	0.1	<0.1	0.01	0.1	<0.1	0.01
Hyperlipidemia	41.3	39.3	0.04	40.7	41.3	-0.01
Hypertensive disorder	61.8	59.4	0.05	61.1	61.5	-0.01
Lesion of liver	1.0	1.0	-0.01	1.0	1.0	-0.01
Lupus erythematosus	0.9	0.2	0.09	0.8	0.2	0.09
Obesity	5.5	5.4	0.00	5.5	5.5	0.00
Osteoarthritis	62.0	59.6	0.05	61.2	61.9	-0.01
Pneumonia	9.1	9.3	-0.00	9.1	9.2	0.00
Psoriasis	2.3	4.9	-0.14	2.7	3.3	-0.04
Renal impairment	11.3	10.5	0.03	11.1	11.2	0.00
Rheumatoid arthritis	88.4	89.7	-0.04	88.9	89.3	-0.01
Schizophrenia	0.1	<0.1	0.00	0.1	0.1	-0.01
Ulcerative colitis	0.6	2.0	-0.12	0.7	1.2	-0.05
Urinary tract infectious disease	13.6	12.7	0.03	13.5	12.7	0.02
Viral hepatitis C	0.5	0.5	-0.01	0.5	0.5	0.00
Visual system disorder	55.4	55.2	0.00	55.3	54.9	0.01
Medical history: Cardiovascular disease						
Atrial fibrillation	10.6	9.5	0.04	10.4	10.2	0.00
Cerebrovascular disease	11.8	11.0	0.02	11.5	11.6	0.00
Coronary arteriosclerosis	19.7	19.8	0.00	19.6	19.3	0.01
Heart disease	44.3	44.4	0.00	44.0	44.7	-0.01
Heart failure	10.1	9.9	0.01	10.0	10.4	-0.01
Ischemic heart disease	10.1	10.1	0.00	10.1	10.3	-0.01
Peripheral vascular disease	6.4	5.5	0.04	6.3	6.0	0.01
Pulmonary embolism	1.5	1.3	0.02	1.5	1.3	0.02
Venous thrombosis	3.4	3.4	0.00	3.3	3.5	-0.01
Medical history: Neoplasms						
Hematologic neoplasm	2.2	2.3	-0.00	2.2	2.4	-0.01
Malignant lymphoma	1.3	1.5	-0.02	1.3	1.4	-0.01
Malignant neoplasm of anorectum	0.4	0.4	0.00	0.4	0.4	0.01
Malignant neoplastic disease	18.5	19.8	-0.03	18.7	18.9	0.00
Malignant tumor of breast	3.8	4.0	-0.01	3.8	3.7	0.00
Malignant tumor of colon	0.8	0.7	0.02	0.9	0.6	0.03
Malignant tumor of lung	0.7	0.6	0.00	0.6	0.5	0.02
Malignant tumor of urinary bladder	1.0	1.2	-0.02	1.0	1.0	0.00
Primary malignant neoplasm of prostate	2.4	2.8	-0.03	2.5	2.4	0.00
Medication use						
Agents acting on the renin-angiotensin system	48.1	47.1	0.02	47.9	48.2	-0.01
Antibacterials for systemic use	46.3	49.0	-0.05	47.0	46.2	0.02
Antidepressants	31.5	31.4	0.00	31.6	31.5	0.00
Antiepileptics	20.1	21.8	-0.04	20.3	20.7	-0.01
Antiinflammatory and antirheumatic products	44.0	44.6	-0.01	44.1	44.9	-0.02
Antineoplastic agents	32.0	40.6	-0.18	34.8	33.0	0.04
Antipsoriatics	1.0	1.3	-0.03	1.0	1.3	-0.02
Antithrombotic agents	22.8	22.1	0.02	22.6	22.3	0.01
Beta blocking agents	39.4	39.4	0.00	39.3	39.1	0.00
Calcium channel blockers	30.1	28.5	0.04	29.6	30.4	-0.02
Diuretics	47.1	45.3	0.04	46.7	46.3	0.01
Drugs for acid related disorders	44.6	45.6	-0.02	44.6	45.1	-0.01
Drugs for obstructive airway diseases	33.2	32.5	0.02	33.1	32.9	0.00
Drugs used in diabetes	17.4	16.9	0.02	17.4	16.9	0.01
Immunosuppressants	41.1	55.1	-0.28	45.5	42.5	0.06
Lipid modifying agents	49.8	48.6	0.02	49.5	49.4	0.00
Opioids	43.6	44.0	-0.01	43.8	43.2	0.01
Psycholeptics	34.6	34.1	0.01	34.5	33.6	0.02
Psychostimulants, agents used for adhd and nootropics	2.0	2.0	0.00	2.0	1.9	0.01

7.9. OpenClaims

	Before PS stratification			After PS stratification		
	HCQ	SSZ	Std. diff	HCQ	SSZ	Std. diff
Characteristic						
Age group	%	%		%	%	
15-19	0.3	0.3	-0.01	0.3	0.3	0.00
20-24	1.2	1.2	-0.01	1.2	1.2	0.00
25-29	1.9	1.9	0.00	1.9	1.8	0.00
30-34	3.0	2.9	0.00	2.9	2.9	0.00
35-39	4.3	4.4	-0.01	4.3	4.3	0.00
40-44	5.8	5.9	0.00	5.8	5.7	0.00
45-49	8.3	8.3	0.00	8.2	8.1	0.00
50-54	11.5	11.9	-0.01	11.5	11.5	0.00
55-59	13.6	14.2	-0.02	13.7	13.8	0.00
60-64	13.4	13.8	-0.01	13.6	13.5	0.00
65-69	12.5	12.7	0.00	12.6	12.6	0.00
70-74	9.9	9.6	0.01	9.9	10.0	0.00
75-79	10.7	9.0	0.06	10.3	10.6	-0.01
80-84	3.7	3.5	0.01	3.6	3.6	0.00
85-89	0.2	0.2	0.00	0.2	0.2	0.00
Gender: female	81.0	73.5	0.18	79.3	79.1	0.00
Medical history: General						
Acute respiratory disease	20.1	19.2	0.02	19.9	19.9	0.00
Attention deficit hyperactivity disorder	0.7	0.7	0.00	0.7	0.7	0.00
Chronic liver disease	2.1	2.0	0.00	2.0	2.1	0.00
Chronic obstructive lung disease	7.6	7.7	0.00	7.6	7.8	0.00
Crohn's disease	0.4	1.6	-0.11	0.5	0.9	-0.04
Dementia	0.8	0.7	0.01	0.8	0.8	0.00
Depressive disorder	9.7	9.6	0.00	9.6	9.8	-0.01
Diabetes mellitus	15.6	16.1	-0.01	15.7	16.0	-0.01
Gastroesophageal reflux disease	4.3	5.0	-0.04	4.5	4.5	0.00
Gastrointestinal hemorrhage	2.4	2.5	-0.01	2.4	2.4	0.00
Human immunodeficiency virus infection	0.2	0.2	0.00	0.2	0.2	0.00
Hyperlipidemia	26.0	25.8	0.01	26.0	26.4	-0.01
Hypertensive disorder	35.0	34.5	0.01	34.9	35.2	-0.01
Lesion of liver	0.8	0.7	0.01	0.8	0.8	0.00
Lupus erythematosus	1.1	0.3	0.10	0.9	0.5	0.05
Obesity	6.3	6.6	-0.01	6.4	6.5	0.00
Osteoarthritis	36.0	37.0	-0.02	36.1	36.9	-0.02
Pneumonia	4.4	4.2	0.01	4.3	4.3	0.00
Psoriasis	1.9	5.4	-0.19	2.2	3.3	-0.06
Renal impairment	6.2	5.5	0.03	6.1	6.0	0.00
Rheumatoid arthritis	69.0	69.6	-0.01	69.3	69.7	-0.01
Schizophrenia	0.2	0.2	0.00	0.2	0.2	0.00
Ulcerative colitis	0.4	1.7	-0.12	0.5	1.0	-0.06
Urinary tract infectious disease	8.7	7.4	0.05	8.4	8.4	0.00
Viral hepatitis C	1.1	1.1	0.00	1.1	1.1	0.00
Visual system disorder	21.9	20.7	0.03	21.6	21.6	0.00
Medical history: Cardiovascular disease						
Atrial fibrillation	3.6	3.4	0.01	3.6	3.6	0.00
Cerebrovascular disease	3.4	2.8	0.03	3.2	3.3	0.00
Coronary arteriosclerosis	6.8	6.8	0.00	6.8	6.9	0.00
Heart disease	18.3	17.3	0.03	18.1	18.3	0.00
Heart failure	4.0	3.7	0.02	3.9	4.0	0.00
Ischemic heart disease	3.5	3.4	0.01	3.5	3.6	0.00
Peripheral vascular disease	9.7	9.1	0.02	9.6	9.6	0.00
Pulmonary embolism	0.8	0.7	0.01	0.8	0.8	0.00
Venous thrombosis	1.5	1.4	0.01	1.5	1.5	0.00
Medical history: Neoplasms						
Hematologic neoplasm	0.9	0.9	0.00	0.9	1.0	0.00
Malignant lymphoma	0.6	0.6	0.00	0.6	0.6	0.00
Malignant neoplasm of anorectum	0.1	0.1	0.00	0.1	0.1	0.00
Malignant neoplastic disease	7.2	7.2	0.00	7.2	7.4	0.00
Malignant tumor of breast	1.8	1.6	0.01	1.7	1.7	0.00
Malignant tumor of colon	0.3	0.3	0.00	0.3	0.3	0.00
Malignant tumor of lung	0.3	0.3	0.00	0.3	0.3	0.00
Malignant tumor of urinary bladder	0.2	0.3	-0.01	0.3	0.3	0.00
Primary malignant neoplasm of prostate	0.6	0.8	-0.02	0.7	0.7	0.00
Medication use						
Agents acting on the renin-angiotensin system	30.8	33.0	-0.05	31.4	31.4	0.00
Antibacterials for systemic use	36.1	38.8	-0.06	36.8	36.6	0.00
Antidepressants	34.5	35.7	-0.03	34.7	34.8	0.00
Antiepileptics	24.0	26.4	-0.05	24.5	24.6	0.00
Antiinflammatory and antirheumatic products	41.0	45.2	-0.08	42.0	41.9	0.00
Antineoplastic agents	31.6	38.0	-0.14	33.3	33.4	0.00
Antipsoriatics	0.7	1.0	-0.03	0.8	0.9	-0.01
Antithrombotic agents	12.9	12.8	0.00	12.9	12.9	0.00
Beta blocking agents	23.1	24.1	-0.02	23.3	23.5	0.00
Calcium channel blockers	17.1	17.1	0.00	17.1	17.1	0.00
Diuretics	28.1	28.8	-0.02	28.3	28.3	0.00
Drugs for acid related disorders	35.3	37.5	-0.04	35.8	35.8	0.00
Drugs for obstructive airway diseases	29.0	31.0	-0.04	29.5	29.5	0.00
Drugs used in diabetes	14.0	15.4	-0.04	14.3	14.6	-0.01
Immunosuppressants	41.9	53.4	-0.23	44.7	44.7	0.00
Lipid modifying agents	29.0	31.5	-0.05	29.6	29.8	-0.01
Opioids	34.8	37.8	-0.06	35.4	35.5	0.00
Psycholeptics	29.5	30.8	-0.03	29.7	29.9	0.00

Psychostimulants, agents used for adhd and nootropics	4.5	4.8	-0.01	4.5	4.6	0.00
---	-----	-----	-------	-----	-----	------

7.10. OptumEHR


	Before PS stratification			After PS stratification		
	HCQ	SSZ	Std. diff	HCQ	SSZ	Std. diff
Characteristic						
Age group	%	%		%	%	
15-19	0.2	0.2	-0.01	0.2	0.2	-0.01
20-24	1.0	1.0	0.00	1.0	1.0	0.00
25-29	1.8	1.9	-0.01	1.8	1.9	-0.01
30-34	3.1	3.1	0.00	3.1	3.0	0.00
35-39	4.2	4.5	-0.02	4.2	4.2	0.00
40-44	5.9	5.7	0.01	5.9	5.5	0.02
45-49	7.9	8.3	-0.01	7.9	7.9	0.00
50-54	11.5	11.7	-0.01	11.6	11.4	0.00
55-59	13.8	14.8	-0.03	14.0	14.2	-0.01
60-64	13.3	13.9	-0.02	13.5	13.5	0.00
65-69	12.1	12.6	-0.02	12.2	12.6	-0.01
70-74	10.0	9.7	0.01	10.0	9.9	0.00
75-79	8.1	7.0	0.04	7.9	7.9	0.00
80-84	5.4	4.3	0.06	5.2	5.3	0.00
85-89	1.5	1.2	0.03	1.5	1.4	0.01
Gender: female	79.9	72.4	0.18	78.2	78.5	-0.01
Race						
race = Asian	1.5	1.1	0.04	1.5	1.4	0.01
race = Black or African American	10.0	8.6	0.05	9.8	9.5	0.01
race = White	81.4	83.3	-0.05	81.7	82.0	-0.01
Ethnicity						
ethnicity = Hispanic or Latino	5.3	6.0	-0.03	5.4	5.4	0.00
Medical history: General						
Acute respiratory disease	17.8	18.6	-0.02	17.9	17.8	0.00
Attention deficit hyperactivity disorder	0.9	0.8	0.01	0.9	0.8	0.01
Chronic liver disease	2.7	3.0	-0.02	2.8	2.9	0.00
Chronic obstructive lung disease	8.5	9.2	-0.03	8.7	8.9	-0.01
Crohn's disease	0.5	1.7	-0.12	0.6	1.0	-0.04
Dementia	1.1	1.0	0.01	1.0	1.1	-0.01
Depressive disorder	15.7	15.5	0.00	15.6	15.4	0.00
Diabetes mellitus	14.9	15.1	-0.01	15.0	15.2	0.00
Gastroesophageal reflux disease	18.3	18.3	0.00	18.3	18.0	0.01
Gastrointestinal hemorrhage	2.1	2.5	-0.02	2.1	2.2	0.00
Human immunodeficiency virus infection	0.1	0.2	-0.01	0.1	0.2	-0.01
Hyperlipidemia	30.3	31.5	-0.03	30.5	30.4	0.00
Hypertensive disorder	38.8	39.0	0.00	38.8	39.1	-0.01
Lesion of liver	1.1	0.9	0.02	1.0	1.0	0.01
Lupus erythematosus	1.0	0.3	0.09	0.9	0.5	0.04
Obesity	11.3	12.3	-0.03	11.4	11.7	-0.01
Osteoarthritis	35.0	36.8	-0.04	35.3	35.4	0.00
Pneumonia	4.9	5.1	-0.01	5.0	4.9	0.00
Psoriasis	1.7	4.6	-0.17	2.0	2.7	-0.04
Renal impairment	7.6	6.9	0.03	7.4	7.5	0.00
Rheumatoid arthritis	84.8	84.8	0.00	84.9	85.1	-0.01
Schizophrenia	0.2	0.1	0.01	0.2	0.2	0.00
Ulcerative colitis	0.4	1.5	-0.12	0.5	0.8	-0.04
Urinary tract infectious disease	7.5	6.4	0.04	7.3	7.0	0.01
Viral hepatitis C	1.2	1.5	-0.02	1.3	1.4	-0.01
Visual system disorder	13.7	13.9	0.00	13.7	13.3	0.01
Medical history: Cardiovascular disease						
Atrial fibrillation	4.5	4.0	0.03	4.5	4.5	0.00
Cerebrovascular disease	3.1	3.1	0.00	3.1	3.0	0.00
Coronary arteriosclerosis	8.3	8.5	-0.01	8.3	8.4	0.00
Heart disease	20.8	20.4	0.01	20.7	21.1	-0.01
Heart failure	4.7	4.4	0.01	4.7	4.8	-0.01
Ischemic heart disease	4.4	4.5	-0.01	4.4	4.4	0.00
Peripheral vascular disease	2.6	2.4	0.01	2.6	2.4	0.01
Pulmonary embolism	1.0	1.1	-0.01	1.0	1.0	-0.01
Venous thrombosis	1.9	2.0	-0.01	1.9	2.0	-0.01
Medical history: Neoplasms						
Hematologic neoplasm	1.1	1.2	-0.01	1.1	1.2	0.00
Malignant lymphoma	0.6	0.7	-0.01	0.6	0.7	-0.01
Malignant neoplasm of anorectum	0.2	0.2	0.01	0.2	0.2	0.01
Malignant neoplastic disease	8.5	8.8	-0.01	8.5	8.7	-0.01
Malignant tumor of breast	1.9	1.7	0.02	1.9	1.9	0.00
Malignant tumor of colon	0.4	0.4	0.00	0.4	0.4	0.00
Malignant tumor of lung	0.4	0.4	-0.01	0.4	0.4	-0.01
Malignant tumor of urinary bladder	0.2	0.4	-0.03	0.2	0.3	-0.02
Primary malignant neoplasm of prostate	0.6	0.9	-0.03	0.7	0.7	0.00
Medication use						
Agents acting on the renin-angiotensin system	30.5	31.8	-0.03	30.8	31.3	-0.01
Antibacterials for systemic use	28.0	30.2	-0.05	28.3	28.1	0.00
Antidepressants	35.9	35.9	0.00	35.9	36.1	-0.01
Antiepileptics	23.9	25.0	-0.03	24.2	24.4	-0.01
Antiinflammatory and antirheumatic products	43.8	47.3	-0.07	44.5	44.3	0.00
Antineoplastic agents	34.7	37.3	-0.05	35.4	36.6	-0.03
Antipsoriatcs	0.6	0.7	-0.01	0.6	0.6	0.00
Antithrombotic agents	32.9	31.7	0.03	32.7	33.1	-0.01
Beta blocking agents	26.7	27.1	-0.01	26.8	27.3	-0.01
Calcium channel blockers	17.1	16.8	0.01	17.1	17.4	-0.01
Diuretics	29.2	28.5	0.02	29.1	29.2	0.00
Drugs for acid related disorders	45.1	45.7	-0.01	45.2	45.4	0.00

Drugs for obstructive airway diseases	34.5	35.5	-0.02	34.7	34.8	0.00
Drugs used in diabetes	15.1	15.9	-0.02	15.3	15.8	-0.02
Immunosuppressants	47.4	55.7	-0.17	49.2	50.3	-0.02
Lipid modifying agents	30.2	31.9	-0.04	30.6	30.9	-0.01
Opioids	39.3	41.5	-0.04	39.7	40.1	-0.01
Psycholeptics	35.1	35.4	-0.01	35.1	35.2	0.00
Psychostimulants, agents used for adhd and nootropics	4.3	4.1	0.01	4.2	4.0	0.01


8. Study diagnostics

Preference score overlap, covariate balance, and empirical calibration plots are reported below. The preference score is a transformation of the propensity score that adjusts for differences in the sizes of the two exposure cohorts in a pairwise comparison. A higher overlap indicates patients in the two cohorts were more similar in terms of their predicted probability of receiving one exposure relative to the other. In the covariate balance plots, each dot represents the standardized difference of means for a single covariate before and after propensity score stratification. The empirical calibration plots show effect estimates for the negative controls where the true hazard ratio is expected to equal 1. Estimates below the diagonal dashed lines are statistically significantly different ($\alpha = 0.05$) from the true effect size. A well-calibrated estimator should produce the true effect sizes within the 95 percent confidence interval 95 percent of the time. Negative control estimates are not reported if fewer than 5 events are observed. *On-treatment* time-at-risk was unavailable in the OptumEHR databases so no negative control effects were estimated.

8.1. Diagnostics (AmbEMR, CCAE, Clininformatics, CPRD, DAGermany)



8.2. Diagnostics (IMRD, MDCD, MDCR, OpenClaims, OptumEHR)



9. Incidence rates

Patient counts, event counts, and incidence rates per 1,000 person-years are reported below for HCQ vs SSZ during the two follow-up periods. Note that the incidence rate does not account for stratification.

9.1. 30-day follow-up

		Patients	TAR		Events		IR			
Outcome	Database	T	C	T	C	T	C	T	C	MDRR
Depression	AmbEMR	55,793	15,092	4,571	1,237	155	29	33.91	23.44	1.66
	CCAE	66,440	22,449	5,395	1,822	79	28	14.64	15.36	1.87
	Clininformatics	51,676	16,812	4,190	1,362	84	41	20.05	30.09	1.79
	CPRD	9,160	11,348	749	930	<5	8	<6.67	8.60	>4.77
	DAGermany	3,937	5,109	322	419	<5	12	<15.48	28.63	>3.94
	IMRD	8,844	8,456	723	692	<5	6	<6.91	8.67	>5.42
	MDCD	7,950	2,286	647	185	14	6	21.61	32.29	4.50
	MDCR	15,735	5,275	1,282	429	13	6	10.14	13.98	4.40
	OpenClaims	620,081	183,312	50,893	15,046	654	161	12.85	10.70	1.26
	OptumEHR	78,528	20,244	6,348	1,637	321	66	50.56	40.30	1.42
Suicide and suicidal ideation	Meta-analysis	918,144	290,383	75,126	23,764	<1,335	363	<17.77	15.28	>1.17
	CCAE	66,533	22,471	5,405	1,825	12	<5	2.22	<2.74	>11.44
	Clininformatics	51,807	16,843	4,203	1,366	12	<5	2.85	<3.66	>11.72
	CPRD	9,167	11,358	750	931	<5	<5	<6.66	<5.37	>Inf
	IMRD	8,852	8,460	723	692	<5	<5	<6.91	<7.22	>Inf
	MDCD	7,980	2,296	650	186	<5	<5	<7.68	<26.78	>Inf
	OpenClaims	621,067	183,550	50,999	15,072	34	8	0.67	0.53	2.80
	OptumEHR	79,903	20,480	6,474	1,659	18	8	2.78	4.82	3.91
	Meta-analysis	845,309	265,458	69,208	21,734	<91	<41	<1.31	<1.89	>2.53
	OpenClaims	620,964	183,527	50,988	15,069	95	27	1.86	1.79	1.83
Hospitalization for psychosis	OptumEHR	79,994	20,508	6,482	1,661	<5	<5	<0.77	<3.01	>Inf
	Meta-analysis	700,958	204,035	57,470	16,731	<100	<32	<1.74	<1.91	>2.25

9.2. On-treatment follow-up

		Patients	TAR		Events		IR			
Outcome	Database	T	C	T	C	T	C	T	C	MDRR
Depression	AmbEMR	55,793	15,092	18,043	5,579	320	80	17.74	14.34	1.41
	CCAE	66,440	22,449	65,249	14,578	557	137	8.54	9.40	1.28
	Clininformatics	51,676	16,812	52,863	11,866	657	178	12.43	15.00	1.25
	CPRD	9,160	11,348	18,063	26,115	36	94	1.99	3.60	1.64
	DAGermany	3,937	5,109	2,585	3,561	40	70	15.47	19.66	1.71
	IMRD	8,844	8,456	17,274	18,765	38	51	2.20	2.72	1.81
	MDCD	7,950	2,286	5,691	1,284	90	13	15.81	10.12	1.94
	MDCR	15,735	5,275	18,059	4,098	97	38	5.37	9.27	1.74
	OpenClaims	620,081	183,312	859,978	171,406	4,810	957	5.59	5.58	1.09
	Meta-analysis	839,616	270,139	1,057,807	257,256	6,645	1,618	6.28	6.29	1.07
Suicide and suicidal ideation	AmbEMR	57,660	15,357	18,837	5,704	6	<5	0.32	<0.88	>967.23
	CCAE	66,533	22,471	65,931	14,687	81	28	1.23	1.91	1.85
	Clininformatics	51,807	16,843	53,786	11,999	97	30	1.80	2.50	1.78
	CPRD	9,167	11,358	18,127	26,379	7	9	0.39	0.34	4.09
	IMRD	8,852	8,460	17,362	18,928	8	6	0.46	0.32	4.47
	MDCD	7,980	2,296	5,764	1,278	56	18	9.71	14.08	2.19
	MDCR	15,752	5,278	18,168	4,125	15	6	0.83	1.45	4.10
	OpenClaims	621,067	183,550	869,744	172,782	321	89	0.37	0.52	1.39
Hospitalization for psychosis	Meta-analysis	838,818	265,613	1,067,722	255,886	591	<191	0.55	<0.75	>1.39
	OpenClaims	620,964	183,527	868,568	172,595	1,108	221	1.28	1.28	1.20